RxDoctor Payments Data

Jiajoyce Richardson

Family · Harrisburg, PANPI 1053449504

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Gilead accounts for 93.3% of it on its own, with 28 other manufacturers making up the rest. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$42,419in general payments, 2019–2025

Across 148 payments — averaging $286.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$40K
  • AbbVie$967
  • AstraZeneca$505
  • Pharmacyclics LLC, An Abbvie Company$180
  • Astellas Pharma US Inc$149
  • Sanofi$126
  • plus $907 from 23 others

What the payments were for

  • Consulting fees$1,2503%
  • Speaking & faculty fees$21,55851%
  • Travel & lodging$16,22738%
  • Food & beverage$3,1107%
  • Education$2741%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,419 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$510,127
Medicare patients
176
Services billed
16,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$10,875
Anastrozole14$231
Dexamethasone17$160
Prochlorperazine Maleate13$97
Ondansetron Hcl20$88

Paid to pharmacies, not to this prescriber.

Other family in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →